AUG 31, 2020 4:36 AM PDT

A Treatment Avenue Opens for a Rare Disorder

WRITTEN BY: Carmen Leitch

Krabbe disease or globoid cell leukodystrophy is a rare disorder that affects about one in every 100,000 infants. It's caused by a mutation in a gene called GALC, which encodes an enzyme called galactosylceramidase. This incurable condition, which destroys the insulation surrounding nerve cells, is usually fatal to patients before age two.

Image credit: Pxhere

The disorder also affects dogs, who get symptoms starting around six weeks of age. It's also fatal for them; the dogs only survive for a few months after the onset of symptoms. Researchers have now used a canine model of Krabbe disease to show that gene therapy can eliminate the symptoms of the disease. Reporting in the Journal of Clinical Investigation (JCI), the scientists found that dogs that received the therapy lived to be at least four years old, apparently with no significant side effects.

"This disease has no good therapy," said senior study author Charles Vite, a professor of neurology. "We've been looking at this disease in dogs since the 1990s, but it was really the shift over to a new gene therapy vector that gave us a chance to treat it with a big effect on the nervous system."

Cells contain small organelles called lysosomes, they are sacs that contain digestive enzymes. Krabbe disease is a lysosomal storage disorder. Normally, the enzyme encoded by the GALC gene would break down lipids, but a mutated GALC enzyme cannot, so stuff builds up inside of the lysosomes. In the case of Krabbe disease, that disrupts the insulation or myelin surrounding nerve cells, which alters nerve signaling. The disorder leads to neurological symptoms, including blindness, deafness, and paralysis.

A risky bone marrow transplant in an infant patient's first month can help relieve the disorder, but it only works in thirty percent of those treated. "A new treatment is really needed," Vite said.

As with any gene therapy, getting the therapeutic materials to the right place in the body and cells poses a challenge. In this work, the scientists successfully used a viral vector that has been used in other gene therapies, the AAV9 vector, which seems likeliest to gain FDA approval. They tried using high and low doses of the therapy at various ages.

"We decided we would inject into the spinal fluid via the back of the head, which is the most effective means of getting to the brain," noted Vite.

The most benefit was seen in dogs that were given a high dose of gene therapy before they showed symptoms; they had more myelination in their brains, and the myelination in their peripheral nervous system was maintained (even though the therapy was injected into the central nervous system).

"That was a huge surprise for us; that injecting a gene therapy in the spinal fluid can positively affect both the central and the peripheral nervous system was really exciting," Vite said.

There was still a benefit for dogs that were treated after symptoms started. Though they had an intermediate form of the disease, they lived significantly longer than dogs that had not gotten any therapy. It shows that trials will have to be careful about the proper dose.

Follow-up studies will examine the molecular impacts of the therapy, as well as how to ensure both dogs and children receive the correct dose. Vite suggested that since this therapy triggered some improvement in the peripheral nervous system, the approach might be useful for other disorders.

"The hope is to use the model as a method to understand the mechanisms at work in peripheral nerves and how we can target peripheral neuropathies," said Vite.

Sources: AAAS/Eurekalert! via University of Pennsylvania, Journal of Clinical Investigation

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUL 26, 2020
Genetics & Genomics
MAIT Cell Disappearance is Connected to a Genetic Mutation
JUL 26, 2020
MAIT Cell Disappearance is Connected to a Genetic Mutation
Mucosal-associated invariant T cells appear to be a critical part of the human immune system, and dysfunction in these c ...
AUG 15, 2020
Genetics & Genomics
How Dermatitis is Linked to Increased Risk of Food Allergies
AUG 15, 2020
How Dermatitis is Linked to Increased Risk of Food Allergies
Small changes in the genome can sometimes have a huge impact, and researchers have found two that increase the risk of e ...
SEP 14, 2020
Genetics & Genomics
Why Defects in One Gene Can Lead to Cancer in Kids
SEP 14, 2020
Why Defects in One Gene Can Lead to Cancer in Kids
While they may occur in adults, a rare, aggressive type of brain cancer called atypical teratoid rhabdoid tumors tend to ...
SEP 21, 2020
Genetics & Genomics
Replicating the Genome With a Twist
SEP 21, 2020
Replicating the Genome With a Twist
Cold Spring Harbor Laboratory scientists have used cryo-EM to learn more about how the human genome is replicated.
OCT 14, 2020
Genetics & Genomics
Robots Are Moving Developmental Biology Forward
OCT 14, 2020
Robots Are Moving Developmental Biology Forward
Researchers have created a robot that can analyze the effects of mutations that occur in portions of the genome that hel ...
OCT 24, 2020
Cannabis Sciences
Researchers Identify Two DNA Regions Behind Cannabis Abuse
OCT 24, 2020
Researchers Identify Two DNA Regions Behind Cannabis Abuse
Researchers at the Washington School of Medicine in St. Louis have identified two regions in our DNA that seem to contri ...
Loading Comments...